Post hoc analysis: alirocumab benefits HeFH and T3HLP patients Results from the German MILOS cohort demonstrate real-world effectiveness and safety of bempedoic acid PCSK9 inhibitors are unlikely to contribute to mood disorders PCSK9 inhibitors may be effective treatment for PAD PACMAN-AMI: new data on lesion-level effects of lipid lowering AT-TARGET-IT shows reduced CV risk with early PCSK9i in ACS

ESC Congress 2022

26-29 August, Barcelona, Spain

Updated lipoprotein(a) consensus paper

News from ESC Congress 26-29 August, Barcelona, Spain The European Atherosclerosis Society (EAS) has published a new consensus statement on lipoprotein(a) (1), parallel to a session at Congress on measurement, testing, interpreting and treating this lipoprotein. Lipoprotein(a) (Lp(a)) is now firmly established as a causal…

Posted on 30 August 2022 | Posted in ESC Congress 2022

About PCSK9 Education and Research Forum

PCSK9 Education and Research Forum is a not-for-profit organisation established by leading researchers in the fields of atherosclerosis, lipids and cardiovascular disease. Our mission is to raise awareness and knowledge of the significant role played by PCSK9 in lipid metabolism and its value as a novel therapeutic target.

Editorial Policy

Unless otherwise indicated, opinions expressed in the PCSK9 Education and Research Forum are those of the contributors. All patients should discuss their medication with their healthcare professional. Although every effort is made to ensure accuracy and avoid mistakes, no liability on the part of the PCSK9 Forum, the editors or the editorial board is accepted for the consequences of any misleading or inaccurate information.

Educational Partners and Supporters